Ⅲ期乳腺癌改良根治术后预后因素分析  

Related prognosis factors analysis on Ⅲ period breast cancer after modified radical surgery

作　　者：陈东升[1] 吴光兴[1] 

机构地区：[1]湛江中心人民医院肿瘤防治中心,广东湛江524037

出　　处：《现代医学》2014年第6期651-654,共4页Modern Medical Journal

摘　　要：目的:探讨Ⅲ期乳腺癌改良根治术后患者复发转移的相关危险因素。方法:回顾性分析我院Ⅲ期乳腺癌患者192例的相关临床病理资料,就其与患者术后复发转移率的关系进行单因素和多因素分析。结果:192例患者的3年复发转移率为21.88%,单因素分析显示,3年复发转移率与年龄、术后放疗、术后规范化疗、病理类型、阳性淋巴结个数、雌激素受体(ER)、孕激素受体(PR)及人表皮生长因子受体(HER2)有关(P<0.05);多因素非条件Logistic回归分析结果显示,术后放疗、术后规范化疗、病理类型、阳性淋巴结个数及ER、PR、HER2的表达是Ⅲ期乳腺癌改良根治术后发生复发转移的高危因素(P<0.05)。结论:术后放疗、术后规范化疗、病理类型、阳性淋巴结个数及ER、PR、HER2的表达是Ⅲ期乳腺癌改良根治术后发生复发转移的独立危险因素。Objective： To expore the related prognosis factors analysis on Ⅲ period breast cancer after modified radical surgery. Methods： 192 patients with Ⅲ period breast cancer after modified radical surgery were retrospectively analyzed fi＇om June 2005 to June 2010, the relationship between relevant clinical pathologic data and relapse and metastasis rate of breast cancer after modified radical surgery underwent a single factor and muhiple factors analysis. Results： In 192 cases of the study, 3-year recurrence metastasis rate was 21.88% single factor analysis showed that 3-years recurrence metastasis rate was related toage, postoperative radiotherapy, chemotherapy, postoperative pathological type, the number of positive lymph nodes, estrogen receptor （ER） and progesterone receptor （PR） and human epidermal growth factor receptor（HER2）. The difference was statistically significant（ P 〈 0. 05 ）. Muhi-factor unconditioned logistic regression analysis revealed that 3-year recurrence metastasis rate were related topostoperative radiotherapy, chemotherapy, postoperative pathological type, the number of positive lymph nodes, the expression of ER, PR, and HER2 （ P 〈 0. 05 ）. Conclusion： postoperative radiotherapy, chemotherapy,postoperative pathological type, the number of positive lymph nodes, the expression of ER, PR, and HER2 are independent risk factors for lymph node metastasis of advanced gastric cancer.

关 键 词：Ⅲ期乳腺癌 复发转移率 影响因素 

分 类 号：R737.9[医药卫生—肿瘤]